Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Valeant Pharmaceuticals International’s (VRX) third quarter 2012 earnings of $1.11 per share (excluding special items but including stock-based compensation expense) was above the Zacks Consensus Estimate of $1.09 and the year-ago earnings of approximately 62 cents per share.
Revenues for the quarter were $884.1 million, up 47.2% from the year-ago period. The year-over-year improvement in revenues was primarily attributable to higher product sales. Revenues surpassed the Zacks Consensus Estimate of $873 million.
Quarterly Highlights
Product sales at Valeant Pharma amounted to $856.9 million during the third quarter of 2012, up 50%. Strong sales in the US Dermatology and the Emerging Markets segments contributed to the increase. Organically, (excluding the impact of acquisitions and foreign exchange), revenues grew 12% from the year-ago quarter.
Research & development (R&D) expenses climbed 9.7% to $19.2 million. Selling, general & administrative (SG&A) expenses for the third quarter of 2012 increased 40% to $188.7 million.
Guidance
Valeant Pharma adjusted its earnings guidance for fiscal 2012. Cash earnings are now expected in the range of $4.60–$4.65 per share (previous guidance: $4.55–$4.75 per share). Valeant continues to expect total revenue in the range of $3.4 billion – $3.6 billion. The Zacks Consensus Estimate for 2012 hints at earnings of $4.50 per share on revenues of $3.5 billion.
Cash earnings for the final quarter of 2012 are expected in the range of $1.30-$1.35 per share (previous guidance: $1.25–$1.45 per share). The guidance does not include new interest expense of 12 cents per share pertaining to Valeant’s impending acquisition of Medicis Pharmaceutical Corporation ( ) . The Zacks consensus Estimate for the fourth quarter of 2012 currently stands at $1.31 per share.
Our Recommendation
We have a Neutral recommendation on Valeant Pharma. Valeant Pharma carries a Zacks #4 Rank (Sell rating) in the short run.